Aller au contenu principal
Retour à l'annuaire
RhumatologueMédecins généralistes et spécialistes👤 Libéral intégral

M. Docteur Joël COSTE

📍 La Ciotat (13)Libéral💶 Secteur 1RPPS 10003337333
📊 Reconnaissance scientifique : 69/100📝 380 articles publiés📚 HAL (8)🏆 1 DU/DIU

✨ Profil synthétique

IA · 29/04/2026

Le Docteur Joël COSTE est un rhumatologue libéral à La Ciotat, titulaire d'un DU en médecine sportive. Il est auteur de 380 publications et possède un h-index de 69, indiquant une production scientifique significative. Ses recherches couvrent notamment les domaines de la polyarthrite rhumatoïde, de l'ostéoarthrose et de l'épidémiologie.

Expertises présumées

  • Polyarthrite rhumatoïde
  • Ostéoarthrose
  • Épidémiologie
  • Gériatrie
  • Médecine sportive
  • Thérapies ciblées (csDMARDs)
  • Essais cliniques

Synthèse automatique à partir des sources publiques (HAL, OpenAlex, theses.fr, ClinicalTrials.gov, FAI²R, ANS). Pas une évaluation clinique. Le médecin peut corriger via son compte.

Diplômes

🎓 DES & spécialité ordinale

  • Rhumatologie (SM)

📚 CES (Certificat d'Études Spéciales)

  • CES Médecine appliquée aux sports
  • CES Rhumatologie

🎯 Capacités

  • Médecine appliquée aux sports (C)

🎓 Diplômes

  • DE Docteur en médecine

Source : Annuaire Santé ANS (FHIR Practitioner.qualification) · Mises à jour quotidiennes.

🏆 DU / DIU rhumato reconnus

Activité de recherche & publications

Source : bases de données publiques (OpenAlex, PubMed).

h-index

69

h articles cités ≥ h fois chacun. Un h de 69 = 69 publications avec 69+ citations.

Citations

16 053

Publications

380

i10-index

175

Thématiques principales

  • Pituitary Gland Disorders and Treatments ×26
  • Adrenal and Paraganglionic Tumors ×24
  • Historical Studies and Socio-cultural Analysis ×22
  • Rheumatoid Arthritis Research and Therapies ×20
  • Osteoarthritis Treatment and Mechanisms ×17

Affiliations FR : Santé Publique France · Hôpital Cochin · Hôpitaux Universitaires Paris-Ouest

Voir sur OpenAlex ↗🆔 ORCID 0000-0001-7674-7192

Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.

Bibliographie

Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).

Localisation

Adresses géocodées via la Base Adresse Nationale (api-adresse.data.gouv.fr). Précision indicative.

Lieux de consultation

Tarifs & secteur de conventionnement

🟢 Secteur 1 — Tarif conventionnéSource CNAM (Annuaire santé Ameli)
Libéral intégral
📊 Comprendre le remboursement

Prendre rendez-vous & contact

🗓 Trouver sur Doctolib📇 Ajouter à mes contacts

Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).

Top publications · les plus citées

  • 1
    Use of high dose cyproterone acetate and risk of intracranial meningioma in women: cohort study

    BMJ (Clinical research ed.) · 2021

    📚 106 citations🎯 RCR 9.69Top 3% NIH🩺 Clinique🔓 Open Access📄 PDF gratuit ↗
    Lire l'abstract Crossref ↓

    Abstract Objective To assess the risk of meningioma associated with use of high dose cyproterone acetate, a progestogen indicated for clinical hyperandrogenism. Design Observational cohort study. Setting Data from SNDS, the French administrative healthcare database, between 2007 and 2015. Participants 253 777 girls and women aged 7-70 years living in France who started cyproterone acetate between 2007 and 2014. Participants had at least one reimbursement for high dose cyproterone acetate and no history of meningioma or benign brain tumour, or long term disease status. Participants were considered to be exposed when they had received a cumulative dose of at least 3 g during the first six months (139 222 participants) and very slightly exposed (control group) when they had received a cumulative dose of less than 3 g (114 555 participants). 10 876 transgender participants (male to female) were included in an additional analysis. Main outcome measure Surgery (resection or decompression) or radiotherapy for one or more intracranial meningiomas. Results Overall, 69 meningiomas in the exposed group (during 289 544 person years of follow-up) and 20 meningiomas in the control group (during 439 949 person years of follow-up) were treated by surgery or radiotherapy. The incidence of meningioma in the two groups was 23.8 and 4.5 per 100 000 person years, respectively (crude relative risk 5.2, 95% confidence interval 3.2 to 8.6; adjusted hazard ratio 6.6, 95% confidence interval 4.0 to 11.1). The adjusted hazard ratio for a cumulative dose of cyproterone acetate of more than 60 g was 21.7 (10.8 to 43.5). After discontinuation of cyproterone acetate for one year, the risk of meningioma in the exposed group was 1.8-fold higher (1.0 to 3.2) than in the control group. In a complementary analysis, 463 women with meningioma were observed among 123 997 already using cyproterone acetate in 2006 (risk of 383 per 100 000 person years in the group with the highest exposure in terms of cumulative dose). Meningiomas located in the anterior skull base and middle skull base, particularly the medial third of the middle skull base, involving the spheno-orbital region, appeared to be specific to cyproterone acetate. An additional analysis of transgender participants showed a high risk of meningioma (three per 14 460 person years; 20.7 per 100 000 person years). Conclusions A strong dose-effect relation was observed between use of cyproterone acetate and risk of intracranial meningiomas. A noticeable reduction in risk was observed after discontinuation of treatment.

  • 2
    Risk of intracranial meningioma with three potent progestogens: A population-based case-control study

    European journal of neurology · 2022

    📚 47 citations🎯 RCR 5.76Top 6% NIH🔓 Open Access📄 PDF gratuit ↗
    Lire l'abstract Crossref ↓

    AbstractBackground and purposeA dose‐dependent association between the use of cyproterone acetate (CPA) and intracranial meningioma has been identified but data for other potent progestogens are scarce. The association was assessed between intracranial meningioma surgery and exposure to three potent progestogens: CPA (≥25 mg/day), nomegestrol acetate (NOMAC) (3.75–5 mg/day) and chlormadinone acetate (CMA) (2–10 mg/day).MethodsIn this nationwide population‐based case–control study, cases underwent surgery for intracranial meningioma in France from 2009 to 2018. They were matched to five control subjects for sex, year of birth and area of residence. Progestogen exposure was defined as progestogen use within the year before surgery for cases or the same date for their controls.ResultsIn total, 25,216 cases were included (75% women, median age 58 years). Progestogen exposure was noted for 9.9% of cases (2497/25,216) and 1.9% (2382/126,080) of controls, with an odds ratio (OR) of 6.7 (95% confidence interval [CI] 6.3–7.1). The OR was 1.2 (1.0–1.4) for short‐term use (<1 year) and 9.5 (8.8–10.2) for prolonged use. A strong association was identified for prolonged use of CPA (OR = 22.7, 95% CI 19.5–26.4), NOMAC (OR = 6.5, 95% CI 5.8–7.2) and CMA (OR = 4.7, 95% CI 4.5–5.3). Progestogen exposure increased the risk of meningioma for all histological grades and anatomical sites, particularly for the anterior and middle skull base: OR = 35.7 (95% CI 26.5–48.2) and 23.9 (95% CI 17.8–32.2) for CPA. The estimated number of attributable cases was 2124 (95% CI 2028–2220) (212/year).ConclusionA strong association between prolonged exposure to potent progestogens and surgery for meningioma was observed. The risk increased from CMA to NOMAC to CPA. Individuals should be informed of this risk.

  • 3
    Prediction of Brain Death After Out-of-Hospital Cardiac Arrest: Development and Validation of the Brain Death After Cardiac Arrest Score

    Chest · 2021

    📚 29 citations🎯 RCR 2.55Top 20% NIH🩺 Clinique

Publications scientifiques (50) — classées par pathologie

Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).

Transversal26

▼

Épidémiologie & registres12

▼

Qualité de vie / PROMs4

▼

Économie santé2

▼

csDMARDs1

▼

Essai clinique1

▼

Gériatrie1

▼

IA en rhumatologie1

▼

Lupus1

▼

Revue / méta-analyse1

▼

Revue générale1

▼

Santé mentale / fatigue1

▼

Datasets & protocoles partagés

Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).

Partager cette fiche

in LinkedIn🟢 WhatsApp✉ Email

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.